12:52 PM EDT, 05/16/2024 (MT Newswires) -- Oragenics ( OGEN ) said Thursday that it is preparing to start a phase 2 clinical trial for its potential intranasal treatment for concussion, ONP-002.

The company said it has secured an ample supply of intranasal devices in preparation for the trial.

Oragenics ( OGEN ) added that it has collaborated with Avance Clinical to facilitate the implementation of the phase 2a trial in emergency departments at level one trauma centers.

Oragenics ( OGEN ) shares were up 5.6% in recent trading.

Price: 1.73, Change: +0.09, Percent Change: +5.62